Literature DB >> 19321339

Synthesis and in vitro activity of new tetrahydronaphtho[1,2-b]azepine derivatives against Trypanosoma cruzi and Leishmania chagasi parasites.

Alirio Palma1, Andrés Felipe Yépes, Sandra Milena Leal, Carlos Andrés Coronado, Patricia Escobar.   

Abstract

Series of 2-exo-aryl-1,4-epoxy-2,3,4,5-tetrahydronaphtho[1,2-b]azepines 3a-k and cis-2-aryl-4-hydroxy-2,3,4,5-tetrahydronaphtho[1,2-b]azepines 4a-j were synthesized and evaluated against free and intracellular live forms of Trypanosoma cruzi and Leishmania chagasi parasites using in vitro assays. Cell toxicity was also analyzed on Vero and THP-1 mammalian cell lines. The compounds 3c, 3f, and 4d were the most active against both live forms of T. cruzi parasites with low mammalian cell toxicity. Some compounds were active on free live forms of L. chagasi parasites but none was active on intracellular amastigotes of L. chagasi infecting THP-1 macrophages.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19321339     DOI: 10.1016/j.bmcl.2008.05.013

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Four differently substituted 2-aryl-2,3,4,5-tetrahydro-1H-1,4-epoxy-1-benzazepines: hydrogen-bonded structures in one, two and three dimensions.

Authors:  Sandra L Gómez; Carlos M Sanabria; Alirio Palma; Ali Bahsas; Justo Cobo; Christopher Glidewell
Journal:  Acta Crystallogr C       Date:  2009-08-19       Impact factor: 1.172

2.  Quantitative Structure-Activity Relationships for Structurally Diverse Chemotypes Having Anti-Trypanosoma cruzi Activity.

Authors:  Anacleto S de Souza; Leonardo L G Ferreira; Aldo S de Oliveira; Adriano D Andricopulo
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

3.  Stereocontrolled addition of Grignard reagents to oxa-bridged benzazepines: highly efficient synthesis of functionalized benzazepine scaffolds.

Authors:  Yuewei Zhang; Qingqing Bao; Ning Zhang; Shuohang Wang; Xue Yu
Journal:  RSC Adv       Date:  2020-11-17       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.